Yu. O. Malinovskaya

Yu. O. Malinovskaya

Auto-generated profile, based on publicly available information

Yu. O. Malinovskaya

Moscow Regional Research and Clinical Institute n.a. M.F. Vladimirskiy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2019 in Transplantologiya. The Russian Journal of Transplantation
Verified
Journal Article
Open access
PDF file
KKK. Yu. Kokina
K. Yu. Kokina
YMYu. O. Malinovskaya
Yu. O. Malinovskaya
ASA. B. Sidorenko
A. B. Sidorenko
YMYa. G. Moisyuk
Ya. G. Moisyuk
ЮМЮ. О. Малиновская
Ю. О. Малиновская
ЯМЯ. Г. Мойсюк
Я. Г. Мойсюк
Recent statistics have shown increased rates of morbidity and mortality from Clostridium difficile infection worldwide. This problem is mainly typical for surgical patients and is associated with an antibiotic therapy and a prolonged hospital stay. Recipients of solid organs are at a high risk of developing severe forms of C. difficile infection due to immunosupression. Existing recommendations for the treatment of C. difficile infection are based on the severity of the disease and do not consider patients after liver transplantation. The aim of this work is to determine an actual tactics for the diagnosis and treatment of C. difficile in organ recipients in clinical practice.

24 June 2024 in Transplantologiya. The Russian Journal of Transplantation
Verified
Journal Article
Open access
PDF file
YMYu. O. Malinovskaya
Yu. O. Malinovskaya
KKK. Yu. Kokina
K. Yu. Kokina
OSO. V. Sumtsova
O. V. Sumtsova
AGA. O. Grigorevskaya
A. O. Grigorevskaya
YMYa. G. Moysyuk
Ya. G. Moysyuk
ЯМЯ. Г. Мойсюк
Я. Г. Мойсюк
Introduction. Impaired liver transplant function in the long term often leads to graft loss and the recipient death. There are many causes for the development of a late liver allograft dysfunction and different types of its clinical presentation, but there is no generally accepted definition. This hinders its timely diagnosis, analysis of its prevalence, and also makes it difficult to compare the performance of transplantation programs.Objective. To determine the clinical and prognostic value of late liver allograft dysfunction.Material and methods. The study included 103 cases of cadaveric liver transplantation from donors diagnosed with brain death to 100 recipients, of whom 36% were men, aged 48 years old (40;56) (18–68) at the time of transplant, having MELD score 17 (14;21) (7–41). The follow-up period was 52 months (20;77) (8–180). The cases where the graft loss occurred earlier than 3 months were excluded.The late liver allograft dysfunction was defined as a dysfunction of the transplanted liver, which was manifested by at least one of three following signs and occurred at more than 3 months after transplantation: 1) increased aspartate aminotransferase, alanine aminotransferase and/or gamma glutamyl transferase, alkaline phosphatase, bilirubin; 2) impaired synthetic function (increased international normalized ratio, decreased antithrombin III, cholinesterase); 3) liver cirrhosis complications (signs of portal hypertension, ascites, encephalopathy). The following limits were chosen as a diagnostic threshold for laboratory parameter abnormalities: more than 2 upper limits of normal for total bilirubin, more than 1.5 upper limits of normal for the levels of alanine or aspartic aminotransferases, more than 1.5 upper limits of normal for gamma-glutamyltransferase or alkaline phosphatase, more than 1.6 of normal for international normalized ratio.Results. Late liver allograft dysfunction was diagnosed at least once in 64% of recipients. Through the postoperative course, the proportion of patients with late dysfunction varied from 22% to 40%. The etiology of late liver allograft dysfunction was viral (38%), unknown (25%), biliary (19%), immune (17%), and vascular (1%). Late liver allograft dysfunction was reversible in 75% of cases, persistent in 17%, progressive in 8% of cases. Progressive late liver allograft dysfunction led to a graft loss in all cases observed.Recipients with late liver allograft dysfunction were found to have had a 33% higher incidence of early allograft dysfunction (OR 4.7, 95% CI [1.8–12.3]); the incidence of biliary dysfunction was 3.1 times higher with distant choledochojejunostomy (OR 3.9, 95% CI [1.1–13.9]); in patients with autoimmune and cholestatic disease, the incidence of immune dysfunction was 4.8 times higher (OR 5.8, 95% CI [1.7–20.3]).Conclusion. The progressive nature of late liver allograft dysfunction negatively affects the results of transplantation and therefore should be considered as an indication for retransplantation. Reversible and persistent variants of late liver allograft dysfunction have favorable) prognosis. If the etiology of late dysfunction is not established, the regular surveillance with monitoring for fibrosis and repeated attempts to clarify the diagnosis should be continued.

15 December 2021 in Transplantologiya. The Russian Journal of Transplantation
Verified
Journal Article
Open access
PDF file
YMYu. O. Malinovskaya
Yu. O. Malinovskaya
KKK. Yu. Kokina
K. Yu. Kokina
YMYa. G. Moysyuk
Ya. G. Moysyuk
OSO. V. Sumtsova
O. V. Sumtsova
ЮМЮ. О. Малиновская
Ю. О. Малиновская
ЯМЯ. Г. Мойсюк
Я. Г. Мойсюк
Introduction. Liver transplantation restores patients' physical and social life, and its quality. The prevalence of low physical activity in liver recipients is unknown as well as the impact of late liver allograft dysfunction on it. Liver transplantation enhances patient's return to the usual physical and social activity and improves the quality of life. However, the prevalence of low physical activity among liver recipients and the impact of the late allograft dysfunction on it, which is a risk factor for obesity and cardiovascular diseases, require studying.The aim of the study was to identify whether the late liver allograft dysfunction influences the physical activity of recipients.Material and methods. The study included 87 liver recipients. We measured anthropometric parameters, physical performance (SPPB, LFI, 6-min walk test), mean step count per day. Late liver allograft dysfunction was determined if elevated transaminases and/or cholestatic enzymes or hepatic failure have been diagnosed later than 3 months posttransplant. Activity trackers were provided to assess physical activity.Results. Median age was 54 years [45;61], 33% were men. The median follow-up period was 36 months [16;64]. The median of the average steps count was 5.9 [4.1;8.7] thousand per day. 60.5% of recipients were sedentary and low active, 24.4% were somewhat active, 15.1% were active. In cases of liver allograft dysfunction, the mean step count was significantly lower than in patients with normal liver function: 4.1 thousand [2.6;5.3] versus 6.8 thousand [4.2;9.4], p=0.003, despite no differences in the physical activity test results.Conclusion. In case of a late liver allograft dysfunction, the physical activity can decrease; 60.5% of liver recipients, in the absence of pathological restriction of movement, have a sedentary and low active lifestyle. Activity trackers may allow identifying patients who need additional check-up or physical training.

21 March 2025 in Transplantologiya. The Russian Journal of Transplantation
Verified
Journal Article
Open access
PDF file
KKK. Yu. Kokina
K. Yu. Kokina
YMYa. G. Moysyuk
Ya. G. Moysyuk
OSOlga V. Sumtsova
Olga V. Sumtsova
AGA. O. Grigorevskaya
A. O. Grigorevskaya
YMYu. O. Malinovskaya
Yu. O. Malinovskaya
ЮМЮ. О. Малиновская
Ю. О. Малиновская
Introduction. Resistant ascites after liver transplantation is a relatively rare complication. At the same time, its presence significantly affects the prognosis and quality of life. Early diagnosis and successful treatment of resistant ascites can improve the long-term outcome. However, the aetiology of post-transplant ascites is heterogeneous, and the identification of the aetiological factor and the choice of treatment method in most cases is a significant problem for clinicians.Objective. To present the review on methods of diagnosis and treatment of resistant ascites in liver recipients in the early posttransplant period.Material and methods. The authors have reviewed the publications covering the main causes of ascites development after liver transplantation, the efficiency of instrumental diagnostic methods and surgical interventions in liver recipients with resistant ascites. The article has also discussed the authors' own observations of severe clinical cases of posttransplant ascites.Conclusions. The preoperative status of the patient, the characteristics of the donor organ and the peculiarities of the surgical intervention should be taken into account in diagnosing the post-transplant ascites aetiology. In the absence of obvious predisposing factors, the patient should be evaluated sequentially to exclude vascular, intrahepatic and extrahepatic causes of ascites. The understanding of the main mechanisms of post-transplant ascites development and a consistent patient evaluation may help clinicians in choosing the treatment method.

16 December 2024 in Transplantologiya. The Russian Journal of Transplantation
Verified
Journal Article
Open access
PDF file
KKK. Yu. Kokina
K. Yu. Kokina
YMYu. O. Malinovskaya
Yu. O. Malinovskaya
OSO. V. Sumtsova
O. V. Sumtsova
AGA. O. Grigorevskaya
A. O. Grigorevskaya
YMYa. G. Moysyuk
Ya. G. Moysyuk
ЯМЯ. Г. Мойсюк
Я. Г. Мойсюк
Background. Benign recurrent intrahepatic cholestasis is a rare inherited disorder characterized by recurrent episodes of severe hyperbilirubinemia and pruritus that resolve spontaneously. However, attacks of cholestasis may persist for several months and in some cases be associated with frequent recurrences, which may be grounds for liver transplantation.Objective. To present a clinical case of debut benign recurrent intrahepatic cholestasis following acute hepatitis A.Results. A 30-year-old patient was admitted at the Liver Transplantation Center of Moscow Regional Research and Clinical Institute n.a. M.F. Vladimirskiy for a prolonged episode of intrahepatic cholestasis with severe coagulopathy after acute hepatitis A. Total bilirubin was elevated up to 835 µmol/L and INR was 3.6. The manifestations of vitamin K-associated coagulopathy were controlled after the first dose of parenteral menadione sodium bisulfite. Glucocorticosteroids, ursodeoxycholic acid and plasmapheresis turned ineffective in the treatment of hyperbilirubinemia. Due to long-persisting cholestasis resistant to conservative therapy, the patient was considered for inclusion to the liver transplant waiting list. However, spontaneous resolution of the cholestatic episode was achieved at 5 months after the onset of manifestations. Benign recurrent intrahepatic cholestasis type 2 was diagnosed on the basis of the specific clinical signs, laboratory blood tests and genetic testing.Conclusion. The present Case Report shows a long-lasting episode of cholestasis with severe coagulopathy in acute hepatitis A in a patient with benign recurrent intrahepatic cholestasis with subsequent spontaneous resolution of the clinical symptoms at 5 months after their manifestation onset. Therefore, the differential diagnosis of benign recurrent intrahepatic cholestasis should be considered prior to liver transplantation in patients with intrahepatic cholestasis.

11 December 2025 in Transplantologiya. The Russian Journal of Transplantation
Verified
Journal Article
Open access
PDF file
YMYa. G. Moysyuk
Ya. G. Moysyuk
KKK. Yu. Kokina
K. Yu. Kokina
OSO. V. Sumtsova
O. V. Sumtsova
AGA. O. Grigorevskaya
A. O. Grigorevskaya
YMYu. O. Malinovskaya
Yu. O. Malinovskaya
ЮМЮ. О. Малиновская
Ю. О. Малиновская
Background . High long-term survival rates have been achieved in liver transplant recipients. However, personalised approaches are still needed for selecting and managing the initial immunosuppressive therapy regimen throughout the entire period of graft function. Objective . To evaluate the outcomes of various immunosuppressive therapy regimens in liver recipients over a period of up to 20 years. Material and methods . A retrospective cohort study was conducted using data from 173 patients who underwent 176 liver transplants between December 2004 and December 2021. The following immunosuppressive drugs were used: tacrolimus, steroids, mycophenolates, and everolimus, as monotherapy and in various combinations. Modifications to the initial regimen were studied in each patient over time, and the frequency with which various regimens were used at 1, 3, 5 and 10 years after transplantation was analyzed. Clinical observations were divided into two groups depending on whether steroids and/or mycophenolates were present (group 2, n=95) or absent (group 1, n=81) in the initial immunosuppression regimen. Results . The median follow-up duration was 79.5 (58;120) (6–220) months, the total duration was 1355 patient-years. The initial immunosuppression regimen included: tacrolimus (100% of patients), mycophenolates (48% of patients), steroids (39% of patients), everolimus (8% of patients). Tacrolimus monotherapy was initially prescribed to 38% of patients. The regimens prescribed at discharge were modified at various times in 77 (44%) patients, in the 1st group in 14 (17.3%), in the 2nd group in 63 (66.3%), (p<0.05). The 10-year survival rate of the initial immunosuppression regimen was 89% in the 1st group, 33% in the 2nd group (p0.05). SCF ≥ 60 ml/min/1.73m 2 was recorded in 76.9% and 48.3% of patients, respectively (p<0.01). Conclusion . Tacrolimus monotherapy or its combination with everolimus are considered optimal for a selective group of adult liver transplant recipients. With careful selection, strict clinical and drug monitoring, these regimens are characterized by the best survival of therapy, minimal risk of rejection, rare development of late graft dysfunction, favorable safety profile in terms of side effects, in particular, nephrotoxicity.